BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial
I'm PortAI, I can summarize articles.
BriaCell Therapeutics Corp. has reported positive Phase 2 clinical trial results for its Bria-IMT™ regimen in metastatic breast cancer patients. Out of 54 heavily pre-treated patients, 9 remain alive 18 to 47 months post-enrollment, surpassing survival benchmarks for standard therapies. The median overall survival for patients treated since 2022 was 15.6 months, with 52% surviving one year and 32% surviving two years. No treatment-related discontinuations were reported, and results will be confirmed in an ongoing Phase 3 study focusing on overall survival as the primary endpoint.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments